| INTRODUCTION
Fingolimod is a sphingosine-1-phospate (S1P) receptor modulator and has disease modifying effect on relapsing-remitting multiple sclerosis (RRMS) (Calabresi et al., 2014; Cohen et al., 2010; Kappos et al., 2006 Kappos et al., , 2010 . In addition to lymphatic and neural tissue (Brinkmann, 2007; Brinkmann et al., 2010; Mandala et al., 2002; Matloubian et al., 2004) , S1P receptors are found in heart and blood vessels (Camm et al., 2014; Vanoli, Pentimalli, & Botto, 2014) .
Initial S1P receptor agonism of fingolimod causes heart rate decrease by activation of G protein-coupled inwardly rectifying potassium (GIRK) channels and vasodilatation via endothelial nitric oxide synthase (eNOS) pathway (Camm et al., 2014) . Fingolimod-related S1P receptor agonism activates Rho-kinase (ROCK) and results in vasoconstriction as well (Camm et al., 2014) . Physiological homeostasis between heart rate and blood pressure is based on several interacting regulatory reflexes, which are altered in part after fingolimod initiation. However, the sequence of changes in cardiovascular autonomic regulation after fingolimod initiation has not been completely revealed.
We studied the cardiovascular autonomic function through heart rate variability (HRV). HRV is a noninvasive method to investigate cardiac autonomic regulation. The components of HRV reflect the modulation of cardiac autonomic regulation and other regulatory systems (Camm et al., 1996) . In addition to systolic and diastolic blood pressure, the difference between these measures, called pulse pressure, mirrors the features of cardiovascular autonomic regulation, too.
In this study, we investigated the first-dose effects of fingolimod on the sequence of changes in cardiovascular autonomic regulation in RRMS patients by measuring HRV and blood pressure during the first 6 hr after fingolimod initiation.
| METHODS

| Population
Twenty-seven patients with RRMS including 16 (59%) women and 11 (41%) men were studied. The characteristics of patients are expressed in Table 1 . The fingolimod treatment was prescribed on clinical basis strictly by an established drug label without randomization. All patients had fingolimod as a second-line treatment due to side effects or lack of efficacy during a first-line treatment. Preceding immunomodulative treatment for RRMS was discontinued at least a day before fingolimod initiation if changed from interferon-1b or glatiramer acetate and at least 2 months before if shifted from natalizumab. The first dose of fingolimod was given at hospital before 10:00 a.m. and all the patients were followed subsequently 6 hr according to the safety instructions.
| Study setup
All patients underwent 24-hr ambulatory ECG recording at the day of fingolimod initiation. To assess cardiovascular autonomic regulation, heart rate was recorded as RR intervals (duration between two consecutive R-peaks in ECG), which was further generated to different HRV parameters in time and frequency domain. Blood pressure was measured in sitting position just before the first dose of fingolimod (0 hr) and subsequently six times hourly postdose (1, 2, 3, 4, 5, and 6 hr). Expanded disability status scale (EDSS) was used to assess neurological disability related to RRMS.
| Ethics approval
Before participating in the study, each patient gave written informed consent after full explanation of the aim and risk of procedures used. The study was approved by the local ethics committee and was conducted according to the Declaration of Helsinki (2013) 
| Acquisition of ECG signal
Twenty-four-hour ambulatory electrocardiogram (ECG) recordings were performed using Schiller Medilog AR12plus recorders (Schiller Medilog; Schiller AG, Switzerland) with a sampling frequency of 250 Hz.
Three bipolar ECG leads were modified chest lead V5, modified chest lead V1, and modified aVF. Digital ECG recordings were read to Darwin Holter analysis system (Schiller Medilog; Schiller AG) and they were exported in MIT-format for the further analyses. Ambulatory ECG recordings were started 1 hr before fingolimod initiation. During the six postdose hours, the patients were observed under sedentary conditions at hospital, although physical activity was not restricted anyway.
| Analysis of heart rate variability
The mean of RR interval was calculated for each postdose hour. The values for different HRV measures were calculated according to the recommendations (Camm et al., 1996) 
| Physiological background of heart rate variability
Heart rate has an inverse relation to the most HRV measures, and thus, lower heart rate (equal to longer RR interval) tends to associate with higher HRV (Monfredi et al., 2014) . Typically, parasympathetic stimulation results in increased HRV, whereas sympathetic stimulation is associated with a decrease in HRV (Camm et al., 1996) . In time domain, parasympathetic activation is typically reflected by increase in pNN50 and rMSSD parameters. In frequency domain, LFnu component is considered mainly to reflect sympathetic and HFnu component to be a marker of parasympathetic cardiac autonomic regulation (Akselrod et al., 1981; Pomeranz et al., 1985) . Correspondingly, LF/HF ratio indicates sympatho-vagal balance of cardiac autonomic regulation (Camm et al., 1996) . In addition, interactions between vasomotor tone, peripheral vascular resistance, thermoregulation and renin-angiotensin system, for example, has an effect on HRV (Akselrod et al., 1981; Reid, 1992; Virtanen et al., 2003) .
| Statistical analyses
Kolmogorov-Smirnov test was applied to verify the normal distribution of variables. In case of nonnormal distribution, logarithmic (ln) transformation was applied for further statistical testing. Results are expressed as mean ± SD. The repeated measures ANOVA was applied to study the overall differences between the measurements at different time points.
Thereafter, the significances of the differences between two specific time points were tested by paired sample t test. All analyses were conducted at the 2-tailed level and a p-value < .05 was considered statistically significant. All statistical analyses were performed using IBM SPSS statistics (version 19; 1989-2010 SPSS Inc, Chicago, IL, USA).
| RESULTS
The mean of RR interval before fingolimod initiation (0 hr) was 741 ± 94 ms. It prolonged significantly already at 1 hr (803 ± 101 ms; p < .01 vs. 0 hr), while the peak value was demonstrated at 5 hr (974 ± 153 ms; p < .05 vs. 0 hr) (Figure 1 ).
The mean of systolic blood pressure was 133 ± 11 mmHg at 0 hr.
As compared to 0 hr, it started to decrease at 2 hr (128 ± 12 mmHg; p < .05), reached its nadir at 4 hr (124 ± 12 mmHg; p < .001) and showed a complete recovery by discharge at 6 hr (135 ± 11 mmHg) (Figure 1 ).
The mean of diastolic blood pressure was 83 ± 11 mmHg at 0 hr. It decreased similarly to systolic blood pressure at 2 hr (78 ± 12 mmHg; p < .01), reached its nadir at 4 hr (74 ± 13 mmHg; p < .001) as well but remained significantly lower at 6 hr (78 ± 10 mmHg; p < .001) as compared to 0 hr (Figure 1 ).
Pulse pressure was 50 ± 10 mmHg at 0 hr and remained stable during the first five postdose hours. However, significantly higher pulse pressure was demonstrated at 6 hr (57 ± 12 mmHg; p < .01) as compared to 0 hr (Figure 1 ).
| Cardiac autonomic regulation after fingolimod initiation
Overall HRV assessed by the SDNN was 91 ± 31 ms at 0 hr. It increased at 2 hr (104 ± 40 ms; p < .05) and reached the highest value at 3 hr (115 ± 46 ms; p < .01) (Figure 2 ).
Cardiac parasympathetic regulation was enhanced already at 1 hr. In the time domain, this was reflected by higher percentage of normal RR interval with duration more than 50 ms different from the previous normal RR interval (pNN50) (12 ± 11%; p = .01) and higher root mean square of successive differences in RR interval (rMSSD) (34 ± 19; p < .01) as compared to 0 hr (8 ± 7% and 28 ± 15, respectively) (Figure 2 ). The highest value of pNN50 was recorded at 5 hr (23 ± 17%; p < .01), whereas rMSSD reached its highest value an hour earlier at 4 hr (55 ± 34; p < .001), as compared to 0 hr (Figure 2 ).
In frequency domain, low frequency in normalized units (LFnu) reflecting sympathetic cardiac regulation was lower (71 ± 11: p < .05) and high frequency in normalized units (HFnu) reflecting parasympathetic cardiac regulation was higher (28 ± 10; p < .05) at 3 hr as compared to 0 hr (77 ± 11 and 21 ± 11, respectively) ( Figure 2 ). Correspondingly, LF/HF ratio was significantly lower at 3 hr (3.17 ± 2.12; p < .01) as compared to 0 hr (5.15 ± 3.71) (Figure 2 ). The peak of HFnu (33 ± 12)
as well as the nadir of LFnu (65 ± 14) and LF/HF ratio (2.94 ± 3.15)
were recorded at the fifth postdose hour (Figure 2 ).
| Recovery of cardiac autonomic regulation
The recovery of cardiac autonomic regulation started 5 hr postdose but was incomplete at the time of discharge (6 hr). RR interval was significantly longer at 6 hr (919 ± 111 ms) than at 0 hr (741 ± 94 ms; p < .001). In addition, pNN50 (18 ± 14% vs. 9.2 ± 7.3%; p < .001), rMSSD (39 ± 19 vs. 28 ± 15; p < .01), and HFnu (28 ± 10 vs. 21 ± 11; p < .01), all reflecting parasympathetic cardiac regulation, were significantly higher at 6 hr as compared to 0 hr, respectively (Figure 2 ). LFnu (71 ± 11 vs. 77 ± 11; p < .01) reflecting sympathetic cardiac modulation and LF/HF ratio (3.40 ± 2.78 vs. 5.15 ± 3.72; p < .01), an index of sympatho-vagal balance, both remained significantly lower at 6 hr as compared to 0 hr, respectively (Figure 2 ). In this study, we demonstrated that several components of cardiovascular autonomic regulation were influenced by fingolimod initiation. Along with a decrease in heart rate, an enhancement in cardiac parasympathetic regulation was found already 1 hr after the first dose of fingolimod. Systolic and diastolic blood pressure started to show lower values 2 hr and sympathetic cardiac regulation 3 hr after fingolimod initiation. Recovery in heart rate, systolic and diastolic blood pressure, as well as in the parameters of cardiac autonomic regulation started to recover toward baseline values started at 5 hr but did not resume completely at the time of discharge. In addition, pulse pressure continued to increase at the time of discharge.
Fingolimod initiation results in heart rate decrease equal to RR interval prolongation (Camm et al., 2014; Vanoli et al., 2014) . This was demonstrated to occur already at the first postdose hour in our study. An enhancement in the parasympathetic components of HRV was logically demonstrated at the first postdose hour, too.
As known, both these phenomena relate to the initial vagomimetic effects of S1P receptor agonism. A close temporal association between RR interval and the parasympathetic components of HRV was demonstrated during the whole entire observation period.
The components of HRV reflecting mainly sympathetic cardiac regulation and sympatho-vagal balance, started to decrease later, 3 hr after fingolimod initiation. Indeed, this is 2 hr later than an enhancement in the parasympathetic components of HRV was demonstrated. This finding supports the hypothesis that more than one cardiovascular regulatory mechanism becomes adjusted after fingolimod initiation. According to our present findings, the different components of cardiovascular autonomic regulation become altered sequentially in real-life RRMS patients.
Systolic and diastolic blood pressure decreased parallel from the second to the fifth postdose hour. However, pulse pressure continued to increase at the time of discharge as systolic blood pressure recovered but diastolic did not. Previously, in large studies, systolic blood pressure has been reported to increase slightly more than diastolic blood pressure after fingolimod initiation (Calabresi et al., 2014; Gold et al., 2014; Kappos et al., 2010) , whereas some studies (Cohen et al., 2010; Kappos et al., 2006) report only the values of mean arterial pressure. To the best of our knowledge, the effect of fingolimod on pulse pressure has not been previously reported. In general, an elevated pulse pressure has been connected with an impaired blood pressure regulation and an increased cardiac stroke volume (Alfie et al., 1999; Virtanen et al., 2003) . An elevated pulse pressure predicts cardiovascular events and even mortality in unselected populations (Benetos et al., 1997; Franklin et al., 1999) . Unfortunately, we do not have any blood pressure data beyond the hospital discharge.
The recovery (shortening) of RR interval started 5 hr after fingolimod initiation, which is consistent with previously described time window (Cohen et al., 2010; Gold et al., 2014; Hilz et al., 2015; Kappos et al., 2010; Rossi et al., 2015) . In our study, recovery of RR interval was demonstrated to occur along with a withdrawal of parasympathetic cardiac enhancement and increase in sympathetic cardiac regulation. However, none of the studied parameters reflecting cardiovascular autonomic regulation demonstrated full recovery by the time of discharge. Indeed, we have previously reported that heart rate and HRV do not recover to pretreatment values even 3 months after fingolimod treatment (Simula et al., 2015 (Simula et al., , 2016 .
The affinity of fingolimod is the highest for S1P1 receptors expressed abundantly on atrial myocytes as well as on endothelial cells, and somewhat lower for S1P3 receptors being more numerous on vascular smooth muscle cells (Camm et al., 2014; Koyrakh et al., 2005) .
Initial S1P agonism by fingolimod is known to activate GIRK channels resulting in heart rate decrease and also activate eNOS promoting vasodilatation. On the contrary, activation of ROCK by fingolimod results in vasoconstriction. Eventually, fingolimod causes down-regulation of S1P1 receptors and consequently shifts endogenous S1P signaling toward S1P2-3 receptors. These well-described pharmacological effects of fingolimod on different regulatory pathways at myocardium and vascular wall obviously occur in different temporal pattern, and thus, may explain the sequential changes demonstrated in cardiovascular autonomic regulation after fingolimod initiation. In addition, adjustment of physiological cardiovascular autonomic regulation in relation to altered S1P receptor profile may rebalance cardiovascular homeostasis.
F I G U R E 2 Changes in heart rate variability during the 6 hr after the first dose of fingolimod. Each time point is compared to predose values at 0 hr. HF, high frequency; LF, low frequency; nu: normalized units; pNN50, the percentage of normal RR interval with duration more than 50 ms different from the previous normal RR interval; rMSSD, the root mean square of successive differences in RR interval SDNN, the standard deviation of all RR intervals. Values are expressed as mean ± SEM. Significances: *p < .05, **p < .01, and *** p < . 
